Methyl iodide → HCID 68786970, compound
Reaction equation
IC.[C:3]([O-])([O-])=O.[K+].[K+].[Cl:9][C:10]1[C:11]([C:29]2[N:33]=[CH:32][NH:31][N:30]=2)=[C:12]([NH:15][C:16](=[O:28])[CH2:17][N:18]2[C:23](=[O:24])[CH:22]=[CH:21][N:20]3[N:25]=[CH:26][CH:27]=[C:19]23)[S:13][CH:14]=1>CN(C=O)C.C(OCC)(=O)C>[Cl:9][C:10]1[C:11]([C:29]2[N:33]=[CH:32][N:31]([CH3:3])[N:30]=2)=[C:12]([NH:15][C:16](=[O:28])[CH2:17][N:18]2[C:23](=[O:24])[CH:22]=[CH:21][N:20]3[N:25]=[CH:26][CH:27]=[C:19]23)[S:13][CH:14]=1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 2
Procedure
Iodomethane (36 mg, 0.255 mmol) and K2CO3 (44 mg, 0.319 mmol) were added to a solution of N-(4-chloro-3-(1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(5-oxopyrazolo[1,5-a]pyrimidin-4(5H)-yl)acetamide (80 mg, 0.212 mmol) in DMF (1 mL). The reaction mixture was stirred at room temperature for 30 minutes and was subsequently diluted with ethyl acetate and washed with brine. The organic phase was dried (Na2SO4), filtered, concentrated under vacuum and purified by preparative HPLC to give N-(4-chloro-3-(1-methyl-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(5-oxopyrazolo[1,5-a]pyrimidin-4(5H)-yl)acetamide. Retention time (min)=3.00, method [7], MS (ESI) 390.1 (M+H); 1H NMR (300 MHz, CD3C1) δ 8.25 (d, J=8.2 Hz, 1H), 7.90 (s, 1H), 7.76 (d, J=2.1 Hz, 1H), 6.79 (s, 1H), 6.22 (d, J=8.2 Hz, 1H), 5.97 (d, J=2.1 Hz, 1H), 5.36 (s, 2H), 3.99 (s, 3H).
Workup
- washwashed with brine
- dry with materialThe organic phase was dried (Na2SO4)
- filtrationfiltered
- concentrationconcentrated under vacuum
- custompurified by preparative HPLC
Sources & evidence
- ORD record
- ord-5add633fa0d14f369a18e96bbed1703b
- Source dataset
- uspto-grants-2013_05
- Patent number
- US08450363B2
Reaction notes
Loading…